Phase 3 N=838 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
Hypertension
Primary: Trough Seated Diastolic Blood Pressure (DBP) Control — 201; 402; 72; 70 patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=468 Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
Schizophrenia
Primary: Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score — 60.4; 61.3; -9.7; -9.2 Units on a Scale…
Phase 3 N=467 Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated A1c (HbA1c) at Week 26 — -1.12; -0.79 percentage point of total HbA1c — p=<.0001
Phase 3 N=100 NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge — 97 Percentage of Participants
Phase 3 N=40 A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
Exocrine Pancreatic Insufficiency · Steatorrhea · Malabsorption Syndromes
Primary: Change in the Coefficient of Fat Absorption (COA-fat Percent) — -34.1; -1.5 percentage COA-fat — p=<0.001
Phase 3 N=4,844 Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
Prostatic Hyperplasia
Primary: Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods. — 29; 27; 40; 14 events…
Phase 3 N=191 Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment — -1.4; -1.6 percent
Phase 3 N=1,250 MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 18 — -2.37; -1.76 Percent — p=<0.001
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 3 N=200 High Dose CVVHDF Compared to Standard Dose CVVHDF
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
Phase 3 N=400 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment — 6.99; 7.50 percentage of total haemoglobin — p=<0.0001
Phase 3 N=929 Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) — -1.0; -1.3; -1.4; -1.3 percentage point of total HbA1c — p=<0.0001
Phase 3 N=1,091 To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated A1c (HbA1c) at Week 26 — -0.69; -0.97; -1.00; 0.09 Percentage point of total HbA1c — p=<0.0001
Phase 3 N=264 Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment — 7.02; 6.75; 8.02 percentage of total haemoglobin — p=<0.0001
Phase 3 N=253 Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia · Prostatic Hyperplasia
Primary: Percent Change From Baseline in the Prostate Volume at Month 6 — -17.00; -2.77 percent change in volume — p=<0.0001